Deep learning-assisted sensitive detection of fentanyl using a bubbling-microchip.

Journal: Lab on a chip
PMID:

Abstract

Deep learning-enabled smartphone-based image processing has significant advantages in the development of point-of-care diagnostics. Conventionally, most deep-learning applications require task specific large scale expertly annotated datasets. Therefore, these algorithms are oftentimes limited only to applications that have large retrospective datasets available for network development. Here, we report the possibility of utilizing adversarial neural networks to overcome this challenge by expanding the utility of non-specific data for the development of deep learning models. As a clinical model, we report the detection of fentanyl, a small molecular weight drug that is a type of opioid, at the point-of-care using a deep-learning empowered smartphone assay. We used the catalytic property of platinum nanoparticles (PtNPs) in a smartphone-enabled microchip bubbling assay to achieve high analytical sensitivity (detecting fentanyl at concentrations as low as 0.23 ng mL in phosphate buffered saline (PBS), 0.43 ng mL in human serum and 0.64 ng mL in artificial human urine). Image-based inferences were made by our adversarial-based SPyDERMAN network that was developed using a limited dataset of 104 smartphone images of microchips with bubble signals from tests performed with known fentanyl concentrations and using our retrospective library of 17 573 non-specific bubbling-microchip images. The accuracy (± standard error of mean) of the developed system in determining the presence of fentanyl, when using a cutoff concentration of 1 ng mL, was 93 ± 0% in human serum ( = 100) and 95.3 ± 1.5% in artificial human urine ( = 100).

Authors

  • Hui Chen
    Xiangyang Central HospitalAffiliated Hospital of Hubei University of Arts and Science Xiangyang 441000 China.
  • Sungwan Kim
    Department of Biomedical Engineering, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Joseph Michael Hardie
    Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital and, Harvard Medical School, Boston, Massachusetts 02139, USA. hshafiee@bwh.harvard.edu.
  • Prudhvi Thirumalaraju
    Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. hshafiee@bwh.harvard.edu.
  • Supriya Gharpure
    Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital and, Harvard Medical School, Boston, Massachusetts 02139, USA. hshafiee@bwh.harvard.edu.
  • Sahar Rostamian
    Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital and, Harvard Medical School, Boston, Massachusetts 02139, USA. hshafiee@bwh.harvard.edu.
  • Srisruthi Udayakumar
    Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital and, Harvard Medical School, Boston, Massachusetts 02139, USA. hshafiee@bwh.harvard.edu.
  • Qingsong Lei
    Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital and, Harvard Medical School, Boston, Massachusetts 02139, USA. hshafiee@bwh.harvard.edu.
  • Giwon Cho
    Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital and, Harvard Medical School, Boston, Massachusetts 02139, USA. hshafiee@bwh.harvard.edu.
  • Manoj Kumar Kanakasabapathy
    Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. hshafiee@bwh.harvard.edu.
  • Hadi Shafiee
    Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. hshafiee@bwh.harvard.edu and Department of Medicine, Harvard Medical School, Boston, MA, USA.